Indeed, in an immunocompetent murine model, the BRAF–MEK inhibitor treatment increased the expression of multiple immunostimulatory molecules, including HMGB1, calreticulin, and IL-1α, from melanoma cells, which led to increased major histocompatibility complex (MHC) -II expression on the tumor-resident DCs [38]. Here, BRAF is linked to melanoma.